NCT05240391View on ClinicalTrials.gov

Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 20, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

May 5, 2022

Conditions
Paracentesis-Induced Circulatory Dysfunction
Interventions
DRUG

Midodrine Hydrochloride

Midodrine hydrochloride for PICD prevention

DRUG

Human Albumin 20%

Human ALbumin 20% for prevention of paracentesis induced circulatory disturbance

Trial Locations (1)

500032

Asian Institute of Gastroenterology, Hyderabad

All Listed Sponsors
lead

Asian Institute of Gastroenterology, India

OTHER

NCT05240391 - Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance | Biotech Hunter | Biotech Hunter